Zynerba Pharmaceuticals (ZYNE) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ZYNE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYNE, but not buy additional shares or sell existing shares.
View ZYNE analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 12-month target prices for Zynerba Pharmaceuticals' shares. Their ZYNE share price forecasts range from $1.11 to $1.11. On average, they expect the company's share price to reach $1.11 in the next year. This suggests that the stock has a possible downside of 17.2%.
View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts.

Zynerba Pharmaceuticals' stock was trading at $0.53 at the start of the year. Since then, ZYNE shares have increased by 152.8% and is now trading at $1.34.
View the best growth stocks for 2023 here.

Zynerba Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 240,600 shares, an increase of 286.8% from the August 15th total of 62,200 shares. Based on an average daily volume of 769,300 shares, the short-interest ratio is currently 0.3 days.
View Zynerba Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ZYNE earnings forecast.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.01.

Amplify Seymour Cannabis ETF holds 220,858 shares of ZYNE stock, representing 0.30% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).

(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Zynerba Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.38%), Renaissance Technologies LLC (1.29%), Bernardo Wealth Planning LLC (0.15%), Wells Fargo & Company MN (0.14%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Armando Anido, Brian Rosenberger, Daniel L Kisner, James E Fickenscher, Kenneth T Jones, Pamela Stephenson and Terri B Sebree.
View institutional ownership trends.

Shares of ZYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZYNE stock can currently be purchased for approximately $1.34.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a market capitalization of $72.28 million. The company earns $-35,040,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The official website for the company is www.zynerba.com. The company can be reached via phone at (484) 581-7505 or via email at investorrelations@zynerba.com.